Mark D Pegram (Mark Pegram)

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 14

Top Topics

Replacement Therapy

Brain Metastases

Metastatic Breast Cancer

Top Venues

NPJ breast cancer

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Molecular cancer therapeutics

Nature biotechnology

This page only lists publications with an associated author ORCID identifier.

Publications

Curigliano Giuseppe, Rebecca Dent, Antonio Llombart-Cussac, Mark D Pegram, Lajos Pusztai, Nicholas C Turner, Giuseppe Viale
Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2- breast cancer. NPJ breast cancer 9 (1) (2023)
Curigliano Giuseppe, Rebecca Dent, Antonio Llombart-Cussac, Mark D Pegram, Lajos Pusztai, Nicholas C Turner, Giuseppe Viale
Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2- breast cancer. NPJ breast cancer 9 (1) (2023)
Mark D Pegram, Christian Jackisch, Stephen R D Johnston
Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer. NPJ breast cancer 9 (1) (2023)
Curigliano Giuseppe, Rebecca Dent, Antonio Llombart-Cussac, Mark D Pegram, Lajos Pusztai, Nicholas C Turner, Giuseppe Viale
Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2- breast cancer. NPJ breast cancer 9 (1) (2023)
Nancy U Lin, Priya Kumthekar, Solmaz Sahebjam, Nuhad K Ibrahim, Anita Fung, Anna Cheng, Alan Nicholas, Jesse Sussell, Mark D Pegram
Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data. NPJ breast cancer 9 (1) (2023)
Cynthia X Ma, Jingqin R Luo, Rachel A Freedman, Timothy J Pluard, Julie R Nangia, Janice Lu, Frances Valdez-Albini, Melody Cobleigh, Jason M Jones, Nancy U Lin, Eric P Winer, P Kelly Marcom, Shana Thomas, Jill Anderson, Brittney Haas, Leslie Bucheit, Richard Bryce, Alshad S Lalani, Lisa Anne Carey, Matthew P Goetz, Feng Gao, Gretchen Kimmick, Mark D Pegram, Matthew J Ellis, Ron Bose
The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (7) (2022)
Hope S Rugo, Seock-Ah Im, Fatima Cardoso, Javier Cortes, Giuseppe Curigliano, Antonino Musolino, Mark D Pegram, Thomas Bachelot, Gail S Wright, Cristina Saura, Santiago Escrivá-de-Romaní, Michelino De Laurentiis, Gary N Schwartz, Timothy J Pluard, Francesco Ricci, William R Gwin, Christelle Levy, Ursa Brown-Glaberman, Jean-Marc Ferrero, Maaike de Boer, Sung-Bae Kim, Katarína Petráková, Denise A Yardley, Orit Freedman, Erik H Jakobsen, Einav Nili Gal-Yam, Rinat Yerushalmi, Peter Andreas Fasching, Peter A Kaufman, Emily J Ashley, Raul Perez-Olle, Shengyan Hong, Minori Koshiji Rosales, William J Gradishar, null null
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Mark D Pegram, Erika P Hamilton, Antoinette R Tan, Anna Maria Storniolo, Kemal Balic, Anton I Rosenbaum, Meina Liang, Peng He, Shannon Marshall, Anita Scheuber, Mayukh Das, Manish R Patel
First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer. Molecular cancer therapeutics 20 (8) (2021)
Sara Alsterlind Hurvitz, Nicholas P McAndrew, Aditya Bardia, Michael F Press, Mark D Pegram, John P Crown, Peter Andreas Fasching, Bent Ejlertsen, Eric H Yang, John A Glaspy, Dennis J Slamon
A careful reassessment of anthracycline use in curable breast cancer. NPJ breast cancer 7 (1) (2021)
Nancy U Lin, Mark D Pegram, Solmaz Sahebjam, Nuhad K Ibrahim, Anita Fung, Anna Cheng, Alan Nicholas, Whitney P Kirschbrown, Priya Kumthekar
Reply to J. Wei et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Nancy U Lin, Mark D Pegram, Solmaz Sahebjam, Nuhad K Ibrahim, Anita Fung, Anna Cheng, Alan Nicholas, Whitney P Kirschbrown, Priya Kumthekar
Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (24) (2021)
Liyang Cui, Arvin M Gouw, Edward L LaGory, Shenghao Guo, Nabeel Attarwala, Yao Tang, Ji Qi, Yun-Sheng Chen, Zhou Gao, Kerriann M Casey, Arkadiy A Bazhin, Min Chen, Leeann Hu, Jinghang Xie, Mingxi Fang, Cissy Zhang, Qihua Zhu, Zhiyuan Wang, Amato J Giaccia, Sanjiv Sam Gambhir, Weiping Zhu, Dean W Felsher, Mark D Pegram, Elena A Goun, Anne Le, Jianghong Rao
Mitochondrial copper depletion suppresses triple-negative breast cancer in mice. Nature biotechnology 39 (3) (2020)
Alexis V Forterre, Jing-Hung Wang, Alain Delcayre, Kyuri Kim, Carol Green, Mark D Pegram, Stefanie S Jeffrey, A C Matin
Extracellular Vesicle-Mediated In Vitro Transcribed mRNA Delivery for Treatment of HER2+ Breast Cancer Xenografts in Mice by Prodrug CB1954 without General Toxicity. Molecular cancer therapeutics 19 (3) (2020)
Robyn M Barfield, Yun Cheol Kim, Stepan Chuprakov, Fangjiu Zhang, Maxine Bauzon, Ayodele O Ogunkoya, Dominick Yeo, Colin Hickle, Mark D Pegram, David Rabuka, Penelope M Drake
A Novel HER2-targeted Antibody-drug Conjugate Offers the Possibility of Clinical Dosing at Trastuzumab-equivalent Exposure Levels. Molecular cancer therapeutics 19 (9) (2020)